BRPI0414268B8 - ácidos 4-((fenoxialquil)tio)-fenoxiacéticos, análogos, e composições farmacêuticas - Google Patents

ácidos 4-((fenoxialquil)tio)-fenoxiacéticos, análogos, e composições farmacêuticas

Info

Publication number
BRPI0414268B8
BRPI0414268B8 BRPI0414268A BRPI0414268A BRPI0414268B8 BR PI0414268 B8 BRPI0414268 B8 BR PI0414268B8 BR PI0414268 A BRPI0414268 A BR PI0414268A BR PI0414268 A BRPI0414268 A BR PI0414268A BR PI0414268 B8 BRPI0414268 B8 BR PI0414268B8
Authority
BR
Brazil
Prior art keywords
phenoxyalkyl
thio
analogs
phenoxyacetic acids
pharmaceutical compositions
Prior art date
Application number
BRPI0414268A
Other languages
English (en)
Inventor
Wang Aihua
r deangelis Alan
Kuo Gee-Hong
Zhang Rui
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414268(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0414268A publication Critical patent/BRPI0414268A/pt
Publication of BRPI0414268B1 publication Critical patent/BRPI0414268B1/pt
Publication of BRPI0414268B8 publication Critical patent/BRPI0414268B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

"ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos". a invenção refere-se a ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos, composições contendo-os e métodos de empregá-los como moduladores de ppar delta para tratar ou inibir a progressão de, por exemplo, dislipidemia.
BRPI0414268A 2003-09-19 2004-09-16 ácidos 4-((fenoxialquil)tio)-fenoxiacéticos, análogos, e composições farmacêuticas BRPI0414268B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50414603P 2003-09-19 2003-09-19
PCT/US2004/030375 WO2005042478A2 (en) 2003-09-19 2004-09-16 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Publications (3)

Publication Number Publication Date
BRPI0414268A BRPI0414268A (pt) 2006-11-07
BRPI0414268B1 BRPI0414268B1 (pt) 2017-04-04
BRPI0414268B8 true BRPI0414268B8 (pt) 2021-05-25

Family

ID=34549183

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414268A BRPI0414268B8 (pt) 2003-09-19 2004-09-16 ácidos 4-((fenoxialquil)tio)-fenoxiacéticos, análogos, e composições farmacêuticas

Country Status (30)

Country Link
US (9) US7301050B2 (pt)
EP (2) EP1667964B1 (pt)
JP (1) JP4928941B2 (pt)
KR (1) KR101111475B1 (pt)
CN (1) CN1882533B (pt)
AR (1) AR045773A1 (pt)
AT (1) ATE542793T1 (pt)
AU (1) AU2004285849B2 (pt)
BR (1) BRPI0414268B8 (pt)
CA (1) CA2539446C (pt)
CO (1) CO5680476A2 (pt)
CR (1) CR8301A (pt)
CY (1) CY1110555T1 (pt)
DE (1) DE602004022179D1 (pt)
DK (1) DK1667964T3 (pt)
EA (1) EA012241B1 (pt)
EC (1) ECSP066434A (pt)
ES (2) ES2378435T3 (pt)
HK (2) HK1092784A1 (pt)
IL (1) IL174398A (pt)
NO (2) NO338511B1 (pt)
NZ (1) NZ545943A (pt)
PL (1) PL1667964T3 (pt)
PT (1) PT1667964E (pt)
SG (1) SG145752A1 (pt)
SI (1) SI1667964T1 (pt)
TW (1) TWI336238B (pt)
UA (1) UA87467C2 (pt)
WO (1) WO2005042478A2 (pt)
ZA (1) ZA200603085B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670744B9 (en) * 2003-09-19 2012-09-05 Janssen Pharmaceutica NV 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
MX2011004077A (es) * 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
CN104487542B (zh) * 2012-07-06 2016-10-12 默克专利股份有限公司 双介晶化合物和介晶介质
EA201691039A1 (ru) 2013-11-20 2016-11-30 Саймабэй Терапьютикс, Инк. Лечение гомозиготной семейной гиперхолестеринемии
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
DK3129018T3 (da) 2014-04-11 2020-01-20 Cymabay Therapeutics Inc Behandling af NAFLD og NASH
MX2016017081A (es) 2014-06-26 2017-05-01 Cymabay Therapeutics Inc Tratamiento de hipertrigliceridemia grave.
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20200276178A1 (en) 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
EP3973959A1 (en) 2017-09-26 2022-03-30 CymaBay Therapeutics, Inc. Treatment of cholestatic pruritus with seladelpar
US10702488B2 (en) * 2017-12-19 2020-07-07 Theriac Biomedical Inc. PPAR-γ activators, HDAC inhibitors and their therapeutical usages
US11497723B1 (en) * 2017-12-19 2022-11-15 Tony Antakly PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
EA202191379A1 (ru) 2018-11-16 2021-08-06 Саймабэй Терапьютикс, Инк. Комбинированное лечение nafld и nash
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
CN112824380A (zh) * 2019-11-21 2021-05-21 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
LT4225291T (lt) 2021-02-01 2024-06-10 Cymabay Therapeutics, Inc. Cholangiopatijų gydymas seladelparu

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517051A (en) * 1964-03-20 1970-06-23 Merck & Co Inc Phenoxy substituted phenylacetic acids
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4109013A (en) * 1974-12-20 1978-08-22 Klinge Pharma Gmbh & Co. Substituted propanol-(2) derivatives of hydroxamic acids and the use thereof as hypolipemic drugs
US4125732A (en) 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3169761D1 (en) * 1981-01-09 1985-05-09 Fisons Plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) * 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
ATE22072T1 (de) 1982-09-30 1986-09-15 Merck Frosst Canada Inc Leukotrienantagonisten, deren herstellung und diese enthaltende zusammensetzungen.
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) * 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
EP0562796A1 (en) 1992-03-23 1993-09-29 Terumo Kabushiki Kaisha Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
DE69733154T2 (de) * 1996-02-02 2006-03-09 Merck & Co., Inc. Verfahren zur behandlung von diabetes und verwandter krankheitszustände.
CA2245529A1 (en) 1996-02-02 1997-08-07 Soumya P. Sahoo Antidiabetic agents
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
WO1999004815A1 (fr) 1997-07-24 1999-02-04 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales hypocholesterolemiantes
ES2281146T3 (es) 1997-12-19 2007-09-16 MERCK & CO., INC. Ariltiazolidindionas utiles como compuestos terapeuticos.
CN1348439A (zh) 1999-04-20 2002-05-08 诺沃挪第克公司 新化合物及其制备和用途
CA2376919C (en) * 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0003310D0 (en) * 2000-02-15 2000-04-05 Univ Sheffield Bone formation
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
SK14912003A3 (sk) 2001-06-07 2004-09-08 Eli Lilly And Company Modulátory receptorov aktivovaných peroxizomálnymi proliferátormi (PPAR)
EP1414778A1 (en) * 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
BRPI0211844B8 (pt) 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
JP4276074B2 (ja) 2001-10-12 2009-06-10 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
AU2003224632A1 (en) 2002-03-01 2003-09-16 Smithkline Beecham Corporation Hppars activators
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
BR0314335A (pt) 2002-09-05 2005-07-26 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
BR0315667A (pt) 2002-10-28 2005-09-06 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento
PL376718A1 (pl) 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki, ich wytwarzanie i stosowanie
ES2384973T3 (es) 2003-02-14 2012-07-16 Biogen Idec Ma Inc. Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas
US20060257987A1 (en) * 2003-08-20 2006-11-16 Gonzalez Valcarcel Isabel Cris Ppar modulators
EP1670744B9 (en) * 2003-09-19 2012-09-05 Janssen Pharmaceutica NV 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs
ATE542793T1 (de) * 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
BRPI0416106A (pt) 2003-10-31 2007-01-02 Janssen Pharmaceutica Nv ácidos 4 -((fenoxialquil)tio)-fenoxiacéticos e análogos
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
CA2571722C (en) 2004-07-01 2012-12-11 F. Hoffmann-La Roche Ag Phenyl derivatives comprising an acetylene group
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
ATE542793T1 (de) 2012-02-15
CO5680476A2 (es) 2006-09-29
DE602004022179D1 (de) 2009-09-03
US20050124698A1 (en) 2005-06-09
EP1667964A2 (en) 2006-06-14
BRPI0414268B1 (pt) 2017-04-04
IL174398A (en) 2013-10-31
ES2328581T3 (es) 2009-11-16
EP1667964B1 (en) 2009-07-22
TWI336238B (en) 2011-01-21
PL1667964T3 (pl) 2010-01-29
KR101111475B1 (ko) 2012-03-15
US8518997B2 (en) 2013-08-27
AU2004285849B2 (en) 2011-04-28
EA012241B1 (ru) 2009-08-28
EA200600440A1 (ru) 2006-08-25
US20120122988A1 (en) 2012-05-17
SG145752A1 (en) 2008-09-29
UA87467C2 (en) 2009-07-27
US9724322B2 (en) 2017-08-08
CA2539446A1 (en) 2005-05-12
JP4928941B2 (ja) 2012-05-09
ZA200603085B (en) 2007-09-26
WO2005042478A3 (en) 2005-07-21
AU2004285849A1 (en) 2005-05-12
US7301050B2 (en) 2007-11-27
NO338511B1 (no) 2016-08-29
US20190192475A1 (en) 2019-06-27
US8106095B2 (en) 2012-01-31
EP2100877B1 (en) 2012-01-25
US20160199342A1 (en) 2016-07-14
WO2005042478A2 (en) 2005-05-12
KR20070018804A (ko) 2007-02-14
HK1092784A1 (en) 2007-02-16
NO20061728L (no) 2006-06-19
US20170304254A1 (en) 2017-10-26
US20230210808A1 (en) 2023-07-06
PT1667964E (pt) 2009-09-02
TW200526561A (en) 2005-08-16
US7635718B2 (en) 2009-12-22
US20100069496A1 (en) 2010-03-18
US20130331453A1 (en) 2013-12-12
US20080085927A1 (en) 2008-04-10
NZ545943A (en) 2009-09-25
NO20150447A1 (no) 2006-06-19
IL174398A0 (en) 2006-08-01
DK1667964T3 (da) 2009-10-26
CA2539446C (en) 2013-12-03
CN1882533A (zh) 2006-12-20
CY1110555T1 (el) 2015-04-29
BRPI0414268A (pt) 2006-11-07
SI1667964T1 (sl) 2009-12-31
EP2100877A1 (en) 2009-09-16
AR045773A1 (es) 2005-11-09
ES2378435T3 (es) 2012-04-12
NO341448B1 (no) 2017-11-13
JP2007505916A (ja) 2007-03-15
HK1137737A1 (en) 2010-08-06
ECSP066434A (es) 2006-09-18
CR8301A (es) 2008-11-24
CN1882533B (zh) 2010-06-09

Similar Documents

Publication Publication Date Title
BRPI0414268B8 (pt) ácidos 4-((fenoxialquil)tio)-fenoxiacéticos, análogos, e composições farmacêuticas
BRPI0515441A (pt) ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos
ECSP066435A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
BRPI0416106A (pt) ácidos 4 -((fenoxialquil)tio)-fenoxiacéticos e análogos
ECSP077320A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
TW200612926A (en) Compounds and compositions as ppar modulators
BRPI0507959A (pt) uso de inibidores e moduladores de tweak para o tratamento de condições neurológicas
BRPI0510679A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
BR0015482A (pt) Antagonistas de difenil leucotrieno de heterociclo substituìdo
BR0206710A (pt) Composição limpadora sólida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF